经核查独立董事周庆权先生、吴杰先生、陶剑虹女士的任职经历以及签署的 相关自查文件，公司董事会认为上述人员未在公司担任除独立董事以外的任何职 务，也未在公司主要股东担任任何职务，与公司以及主要股东之间不存在利害关 系或其他可能妨碍其进行独立客观判断的关系，不存在其他影响独立董事独立性 的情况。公司独立董事符合《上市公司独立董事管理办法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》等相关法律法规及制度中对独立董事独立性的相关要求。 根据《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等要求，广州市香雪制药股份有限公司（以下简称"公司"）董事会就公司在任 独立董事周庆权先生、吴杰先生、陶剑虹女士的独立性情况进行评估并出具如下 专项意见： 2025 年 4 月 28 日 广州市香雪制药股份有限公司 董事会对独立董事独立性情况的专项意见 广州市香雪制药股份有限公司董事会 ...

Financial Performance - Revenue for Q1 2025 was ¥421,004,187.88, a decrease of 25.99% compared to ¥568,856,745.84 in the same period last year[4] - Net profit attributable to shareholders was -¥87,732,945.81, representing a decline of 146.03% from -¥35,659,979.04 year-over-year[4] - The net cash flow from operating activities was -¥82,460,305.69, a significant drop of 419.44% compared to ¥25,813,931.15 in the previous year[4] - The basic and diluted earnings per share were both -¥0.13, a decline of 160.00% from -¥0.05 in the same period last year[4] - The weighted average return on equity was -8.68%, down 6.81% from -1.87% year-over-year[4] - Total operating revenue for the current period is ¥421,004,187.88, a decrease of 26.0% from ¥568,856,745.84 in the previous period[19] - The net profit for the current period is a loss of ¥80,072,625.44, compared to a loss of ¥28,629,807.17 in the previous period, representing an increase in loss of 179.5%[20] - The total comprehensive income for the current period is a loss of ¥80,115,222.89, compared to a loss of ¥28,625,879.70 in the previous period[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,443,659,743.86, a decrease of 0.73% from ¥7,498,398,859.64 at the end of the previous year[4] - The company's cash and cash equivalents decreased from ¥131,741,496.06 to ¥57,521,160.42, a decline of approximately 56.4%[16] - Accounts receivable increased from ¥810,129,690.20 to ¥908,036,996.48, representing a growth of about 12.1%[16] - Inventory decreased from ¥340,919,525.62 to ¥311,394,935.92, a reduction of approximately 8.7%[16] - Total current liabilities increased from ¥5,382,016,741.51 to ¥5,777,245,299.89, an increase of about 7.3%[17] - The company's total assets decreased from ¥7,498,398,859.64 to ¥7,443,659,743.86, a decline of approximately 0.7%[17] - The total equity attributable to shareholders decreased from ¥1,054,899,213.92 to ¥967,123,670.66, a decrease of about 8.3%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 50,635[10] - The largest shareholder, Guangzhou Kunlun Investment Co., Ltd., held 22.59% of the shares, totaling 149,409,921 shares[10] Government and Regulatory Matters - The company reported a government subsidy of ¥1,202,742.95 during the period[5] - The company has not yet received a formal administrative penalty decision from the regulatory authority regarding the previous non-operating fund occupation[12] Operational Changes - The company has completed the repayment of non-operating funds occupied by the controlling shareholder, totaling ¥3,679,200.00, through a debt offset arrangement[12] - The company is currently undergoing a pre-restructuring process with appointed temporary managers to oversee the proceedings[14] - The company reported a significant increase in accounts receivable financing from ¥7,747,175.19 to ¥1,089,738.65, indicating a shift in financing strategy[16] Expenses - Total operating costs for the current period are ¥484,017,651.17, down 18.1% from ¥591,588,915.65 in the previous period[19] - Research and development expenses for the current period are ¥15,977,095.47, a decrease of 7.8% from ¥17,327,643.17 in the previous period[19] - The company incurred a credit impairment loss of ¥1,241,310.64, compared to a loss of ¥568,029.24 in the previous period[20] Audit Status - The company has not yet audited the first quarter report for the current year[25]

证券代码:300147 证券简称:ST 香雪 公告编号:2025-014 广州市香雪制药股份有限公司 2025 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无变更、否决议案的情况。 2、本次股东会采取现场投票与网络投票表决相结合的方式召开。 一、会议召开和出席情况 1、广州市香雪制药股份有限公司（以下简称"公司"）于 2025 年 4 月 4 日 以公告形式发出《广州市香雪制药股份有限公司关于召开 2025 年第一次临时股 东会的通知》。 2、会议召开方式：本次股东会采取现场投票与网络投票表决相结合的方式。 1 3、会议召开日期和时间 公司部分现任董事、监事、高级管理人员和公司聘请的见证律师等相关人士 出席了会议。北京大成（广州）律师事务所吕晖律师和张秀婷律师见证了本次股 东会并出具了法律意见书。 现场会议召开日期和时间：2025 年 4 月 21 日（星期一）上午 10:00 网络投票日期和时间：2025 年 4 月 21 日。其中，通过深圳证券交易所交易 系统进行网络投票的时间为 2025 年 4 ...

Core Insights - The introduction of the "Qizhi" AI model by Guang'anmen Hospital represents a significant upgrade in the application of AI within traditional Chinese medicine (TCM), aiming to enhance diagnostic efficiency and patient care [1][2] - The model integrates various medical scenarios and TCM-specific data, allowing for multi-modal analysis and improving the overall diagnostic capabilities of TCM practitioners [1][2] - The AI model is expected to standardize and elevate the diagnostic skills of TCM practitioners across hospitals, potentially leading to a transformative impact on the industry [2][9] Group 1: AI Integration in TCM - Guang'anmen Hospital's "Qizhi" model is the first localized deployment of an integrated AI service in TCM, covering outpatient, inpatient, and surgical scenarios [1] - The model utilizes patient data from over 10,000 daily consultations to continuously learn and improve its diagnostic capabilities [1][11] - The AI aims to assist rather than replace TCM practitioners, allowing them to focus on service quality and patient experience [1][2] Group 2: Industry Trends and Challenges - The TCM industry is experiencing a surge in AI model development, with over 10 publicly released models and at least 50 in development by various institutions [2][5] - The need for modernization, internationalization, and standardization in TCM is critical for its survival and growth, with AI models seen as a key driver for this transformation [6][10] - Recent changes in healthcare payment policies are pressuring TCM practitioners to enhance their service capabilities, further driving the adoption of AI technologies [4][10] Group 3: Market Potential - The TCM health industry in China reached a scale of 1.28 trillion yuan in 2022, with projections to exceed 1.8 trillion yuan by 2025, indicating a substantial market opportunity for AI applications [14] - The demand for TCM services has been growing rapidly, with a reported increase of over 25% in TCM outpatient services in 2023 [13] - The integration of AI in TCM is expected to create a market space worth billions, highlighting the financial potential of AI-driven solutions in the healthcare sector [14] Group 4: Data and Research - Guang'anmen Hospital has accumulated a vast amount of clinical data, including 4.07 million case records and 14 million clinical knowledge entries, making it one of the most data-rich TCM institutions in China [11][12] - The challenge of standardizing TCM practices remains, as the field is characterized by subjective interpretations and a lack of unified treatment protocols [10][24] - The development of AI models in TCM is hindered by the need for high-quality, structured data, which is currently lacking in the industry [10][20]

Group 1 - The stock price of ST Xiangxue (300147) closed at 4.95 yuan, down 17.77% as of April 7, 2025, with a turnover rate of 6.27% and a trading volume of 412,200 hands, amounting to 224 million yuan [1] - The latest financial results for ST Xiangxue show total operating revenue of 1.534 billion yuan, a year-on-year decrease of 11.26%, and a net profit attributable to shareholders of 217.8 million yuan, down 49.10% year-on-year [1] - The company has a current ratio of 0.360, a quick ratio of 0.279, and a debt-to-asset ratio of 73.72% [1] Group 2 - ST Xiangxue has made investments in 39 companies and participated in 2,125 bidding projects, indicating active engagement in business expansion [2] - The company holds 242 trademark registrations and 166 patents, showcasing its focus on intellectual property [2] - Additionally, ST Xiangxue possesses 239 administrative licenses, reflecting its compliance and operational capabilities [2]

Core Viewpoint - The clinical trial for TAEST16001, a groundbreaking TCR-T cell therapy for advanced soft tissue sarcoma, has received official recognition from China's CDE, marking a significant milestone in the field of immunotherapy in China [1][2]. Group 1: Clinical Trial Details - The expert seminar for the confirmatory clinical trial of TAEST16001 was held in Guangzhou, with participation from key stakeholders including principal investigators and investment partners [1]. - TAEST16001 has shown promising results in exploratory Phase II clinical trials, with an objective response rate (ORR) of 62.5% and a median progression-free survival (mPFS) of 5.9 months [3]. - The Phase I trial involved 12 patients with advanced soft tissue sarcoma, showing a good tolerance profile and an ORR of 41.7% [2]. Group 2: Product Significance - TAEST16001 is the first TCR-T cell therapy in China to be included in the breakthrough therapy list by the CDE, representing a significant advancement in the treatment of advanced solid tumors [2]. - The therapy utilizes engineered T cells to target tumor antigens, creating a "cell missile" effect for enhanced tumor destruction [2]. - The successful organization of the expert seminar is expected to facilitate the smooth progress of the confirmatory clinical trial and expedite the product's market launch [3].

Core Viewpoint - Guangzhou Xiangxue Pharmaceutical Co., Ltd. has been penalized for continuous financial misreporting and concealing significant related-party fund occupation, leading to a total fine of 20.65 million yuan for the company and its executives, with the actual controller Wang Yonghui facing a five-year market ban [1][3] Financial Misconduct - The financial misconduct of Xiangxue Pharmaceutical dates back to 2016, involving inflated profits and related-party fund occupation exceeding 4.85 billion yuan from 2016 to 2020 [2] - In 2019, the company failed to recognize losses from the demolition of five villas, resulting in an inflated profit of 53.83 million yuan, which accounted for 45.98% of the total profit for that year [2] - The company concealed significant fund occupation, with a discrepancy of 332 million yuan in the 2020 annual report, only partially disclosing the actual fund occupation of 959 million yuan [2] Regulatory Penalties - The China Securities Regulatory Commission (CSRC) has imposed a fine of 6 million yuan on Xiangxue Pharmaceutical and has held six executives accountable, with Wang Yonghui fined 10 million yuan and banned from the market for five years [3] - The stock will be marked with a risk warning and renamed "ST Xiangxue" starting March 25, which may further undermine investor confidence and increase stock price volatility [3] Financial Performance and Debt Crisis - Xiangxue Pharmaceutical has faced declining performance, reporting a net loss of 677 million yuan in 2021, followed by losses of 530 million yuan in 2022 and 389 million yuan in 2023 [4] - As of the end of Q3 2024, the company's debt ratio reached 73.72%, with total liabilities of 5.937 billion yuan, significantly exceeding the industry average of 40%-60% [4] - Despite attempts to streamline operations through asset sales and impairment provisions, the core business has struggled to grow, leading to ongoing cash flow pressures [4] Industry Implications - The case of Xiangxue Pharmaceutical serves as a warning to listed companies regarding compliance with information disclosure regulations, as regulatory bodies continue to crack down on financial fraud and fund occupation [5] - The company faces a critical challenge in restoring its reputation and addressing its debt crisis to maintain its listing status, marking the beginning of a long self-rescue journey [5]

Core Viewpoint - ST Xiangxue Pharmaceutical has faced severe penalties and stock price declines due to significant financial misconduct, including undisclosed related-party transactions and inflated profits, leading to a loss of investor confidence and regulatory scrutiny [1][2][3] Group 1: Financial Misconduct - The company reported a cumulative undisclosed related-party non-operating fund occupation of 4.852 billion yuan from 2016 to 2020, constituting a major violation of disclosure regulations [1][2] - In 2019, ST Xiangxue inflated its profits by 53.83 million yuan, accounting for 45.98% of its total profit for that year, by failing to recognize losses from the demolition of its properties [2] - The Guangdong Securities Regulatory Commission has proposed a fine of 6 million yuan for the company and 10 million yuan for the controlling shareholder Wang Yonghui, who will also face a five-year market ban [2] Group 2: Stock Market Impact - Following the announcement of penalties, ST Xiangxue's stock price hit the daily limit down of 20% for two consecutive days, closing at 8.02 yuan per share on March 25 and further dropping to 6.42 yuan per share on March 26 [2] - The stock's trading volume reflected significant panic, with over 380 million yuan in sell orders on the limit down [2] Group 3: Company Background and Future Challenges - The financial issues stem from the company's acquisition of the Guangzhou Biotech Island project in 2017, which involved complex financial maneuvers and asset transfers that led to cash flow problems [3] - ST Xiangxue has reported losses for four consecutive years, with cumulative losses exceeding 2.5 billion yuan from 2021 to 2024 and a debt ratio of 73.72% [3] - The company is under pressure to resolve over 7.26 billion yuan in short-term overdue loans and has been recognized by the court as lacking the ability to repay debts [3]

星标 ★ IPO日报 精彩文章第一时间推送 两家公司因为存在虚假记载，公司股票交易将被实施其他风险警示！ 3月23日晚间， 香雪制药 (300147)发布公告称，公司收到中国证监会发出的《行政处罚事先告知书》，因公司披露的2019年年度报 告存在虚假记载，公司股票交易将被实施其他风险警示，股票简称由"香雪制药"变更为"ST香雪"。 朗源股份 (300175)同一天披露公告称，近日收到山东证监局出具的《行政处罚事先告知书》，因公司2019年年度报告和更正公告存 在虚假记载，深圳证券交易所将对公司股票交易实施其他风险警示，股票简称由"朗源股份"变更为"ST朗源"。 制图：佘诗婕 存在虚假记载 具体来看，最新披露的《行政处罚事先告知书》显示，香雪制药2019年年度报告存在虚假记载。2019年12月，香雪制药位于广州生 物岛上5栋别墅被相关政府部门拆除香雪制药未按规定确认拆除别墅产生的在建工程损失，导致2019年年度报告虚增利润5383.25万 元，占当期披露利润总额的45.98%，2019年年度报告存在虚假记载。 另外，香雪制药未按规定披露关联方非经营性资金占用，2016年至2020年年度报告存在重大遗漏。2016 ...

年报虚假记载、连续五年存重大遗漏，香雪制药难 逃"ST" 广州市香雪制药股份有限公司（以下简称香雪制药）披露的最新公告，让公司持续数年的年报虚假记 载、因未按规定披露关联方非经营性资金占用导致的重大遗漏等事项有了初步结果，根据证监会广东监 管局发出的《行政处罚事先告知书》，香雪制药及多位高管拟被处以合计2065万元罚款，实控人王永辉 拟被采取5年市场禁入措施，公司股票简称也将从3月25日起变更为"ST香雪"。香雪制药的"雷"不止于 此，高企的负债率和连年亏损的业绩，都让这家企业举步维艰。 连续五年年报存在重大遗漏 3月24日，香雪制药披露，近日收到证监会广东监管局发出的《行政处罚事先告知书》，公司及实控人 王永辉涉嫌信息披露违法违规一案，已调查完毕，并拟作出行政处罚。早在2024年9月30日，香雪制药 及王永辉收到证监会下发的《立案告知书》，公司及王永辉被证监会立案。 此外，由于未按规定披露关联方非经营性资金占用，香雪制药2016年至2020年年度报告存在重大遗漏， 主要涉及香雪制药控股股东广州市昆仑投资有限公司（以下简称昆仑投资）等。 具体来看，2016年至2020年，香雪制药以购买信托理财、中药材合作经营 ...